April 13, 2021

Boehringer Ingelheim introduces new-generation Marek's disease vaccine in EU and UK

Boehringer Ingelheim announced that it has introduced PREVEXXION^® RN in the European Union and the United Kingdom. It is the first innovation in the Marek category of vaccines in over 40 years.

The vaccine provides early onset of immunity against Marek's disease from five days of age for broilers, layers and breeders, and is effective against the most virulent virus strains.

PREVEXXION RN range is composed of an innovative serotype-1 construct vaccine with a unique balance between safety and efficacy.

PREVEXXION RN+HVT+IBD is a convenient and high-performance solution combining PREVEXXION RN and VAXXITEK^® HVT+IBD in one ampoule. This 3-in-1 solution is specifically designed to answer customer needs in long-life bird segments with the most appropriate protection from the hatchery. PREVEXXION RN vaccines are available in ampoules of 1000, 2000, and 4000 doses, frozen in liquid nitrogen.

Jerôme Baudon, head of Poultry at Boehringer Ingelheim, says, "Our PREVEXXION RN range provides value through innovation to Marek-sensitive poultry producers looking for continuous live production productivity improvement and effective protection. Field and lab experiments conducted worldwide demonstrated its safety, efficacy and its strong, early, and long-lasting protection through the lifespan of the birds and against very virulent Marek's disease challenge. PREVEXXION RN is the new golden standard for Marek's disease vaccination programs".

This PREVEXXION launch completes the availability of the PREVEXXION RN range worldwide.

To know more about PREVEXXION RN range, please contact your Boehringer Ingelheim representative.